Mental Health Weekly最新文献

The resident expert at the Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) said he was not surprised by the fluctuations evident in new ADHD (attention-deficit/hyperactivity disorder) research that highlights trends in ADHD and published online in Psychiatric Research and Clinical Practice (see related story, beginning on page 3).

Editor's note: Mental Health Weekly readers continue to weigh in on some of the challenges and opportunities that await them in 2025. Here are more of their comments.

The Substance Abuse and Mental Health Services Administration (SAMHSA), has awarded 14 states and Washington, D.C. with $1 million, one-year Certified Community Behavioral Health Clinic (CCBHC) Medicaid Demonstration Program planning grants, with funding authorized by the Bipartisan Safer Communities Act of 2022 to address the ongoing national mental health and substance use disorder crises, according to a Jan. 7 U.S. Health and Human Services news release stated.

The American Academy of Child and Adolescent Psychiatry (AACAP) has issued a Call for Papers for its Annual Meeting to be held Oct. 20–25 in Chicago, Ill. AACAP is planning for an in-person meeting in Chicago and as such, will require all presenters to be in-person in Chicago for their presentation. Topics may include any aspect of child and adolescent psychiatry that advance the field and can be used to improve the well-being of children and their families. For more information and requirements visit https://aacap.confex.com/aacap/2025/cfp.cgi.

The American Association for Geriatric Psychiatry is holding its 2025 Annual Meeting, “Human Rights and Mental Health Advocacy for Aging Adults,” March 14–17, 2025 in Phoenix, Arizona. For more information, visit https://aagponline.org/education-events/annual-meeting.

Transforming behavioral health crises response around the world for individuals experiencing a mental health or substance use crisis and doing so with dignity and engagement represent the cornerstone of newly developed Global Crisis Care Principles released by health leaders and stakeholders Jan. 6.

Could taking a walk help if you're feeling down? New research in JAMA Network Open says the more steps we take, the less likely we are to feel depressed, WUSF NPR reported Jan. 5. Researchers analyzed 33 studies examining the movements of nearly 100,000 adults using smartphones, pedometers and other fitness trackers. Those who clocked more daily steps were less likely to report depressive symptoms or be diagnosed with the condition than those who walked less. Participants ranged in age from 18 to 91 years old and lived in 13 different countries. Those who logged at least 5,000 or more daily steps were less likely to experience depressive symptoms, with the greatest effect coming for those who logged more than 7,500 steps a day — they were 42% less likely to suffer depressive symptoms. “Studies like these are encouraging because they're not saying that you have to be a marathon runner or go to a really intense class, but you can accumulate the type of movement that's beneficial for your mental health in more gentle ways,” said Karmel Choi, a clinical psychologist and assistant professor at Harvard Medical School, who was not involved with the meta-analysis.

Mental health research using neuroimaging has not been designed to capture sociodemographic factors that influence biology and behavior, a group of research professionals argues in a newly published paper. The authors' recommendations for more inclusivity in these studies have relevance to all aspects of mental health research, as well as to biomedical research in general.

Recognizing the need to expand the state's behavioral health workforce and create culturally inclusive environments for students, the U.S. Department of Education (DOE) has awarded a five-year $3.75 million grant to support an initiative to improve mental health and education in Cincinnati.

Results of new psychedelic research aimed at patients with severe treatment resistant depression (TRD) found significant decreases in their depressive symptoms. Researchers of the open-label study also found significant safety and efficacy of synthetic psilocybin in TRD patients.